Videos
Increasing M&A deals and cutting edge therapies are driving biotech ETFs higher.

IShares Nasdaq Biotechnology ETF: https://www.zacks.com/funds/etf/IBB/profile?cid=CS-YOUTUBE-FT-VID
SPDR S&P Biotech ETF: https://www.zacks.com/funds/etf/XBI/profile?cid=CS-YOUTUBE-FT-VID
ARK Genomic Revolution ETF: https://www.zacks.com/funds/etf/ARKG/profile?cid=CS-YOUTUBE-FT-VID
Virtus LifeSci Biotech Clinical Trials ETF: https://www.zacks.com/funds/etf/BBC/profile?cid=CS-YOUTUBE-FT-VID
ALPS Medical Breakthroughs ETF: https://www.zacks.com/funds/etf/SBIO/profile?cid=CS-YOUTUBE-FT-VID
Merck: https://www.zacks.com/stock/quote/MRK?cid=CS-YOUTUBE-FT-VID
Biogen: https://www.zacks.com/stock/quote/BIIB?cid=CS-YOUTUBE-FT-VID
Sanofi: https://www.zacks.com/stock/quote/SNY?cid=CS-YOUTUBE-FT-VID
ArQule: https://www.zacks.com/stock/quote/ARQL?cid=CS-YOUTUBE-FT-VID
Synthorx: https://www.zacks.com/stock/quote/THOR?cid=CS-YOUTUBE-FT-VID

Follow us on StockTwits: http://stocktwits.com/ZacksResearch
Follow us on Twitter: https://twitter.com/ZacksResearch
Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch

Articles You May Like

Alameda Research files $90M ‘aggressive’ lawsuit against Waves founder
Voters approve Columbus-area transit tax that will back bonds
DeltaPrime exploited for $4.8M worth of ARB and AVAX tokens
Global carbon trading deal agreed even as US warns climate fight may be on ‘back burner’
Consumer anger over high prices piles pressure on politicians